Carcinoma, Intraductal, Noninfiltrating - 6 Studies Found

Active, not recruiting : Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)
: Carcinoma, Intraductal, Noninfiltrating
: 2016-08-10
: Drug: Pembrolizumab Other Names:
  • Keytruda
  • MK-3475
Completed : Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
:
  • Carcinoma, Intraductal, Noninfiltrating
  • DCIS
  • Drug: Chloroquine Standard Dose (500mg/week)

Recruiting : Women Informed to Screen Depending on Measures of Risk
:
  • Breast Neoplasms
  • Carcinoma, Intraductal, Noninfiltrating
    • <
    : 2015-12-01
    :
    • Other: Complete a health questionnaire

Not yet recruiting : Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast
: Breast Cancer
: 2008-11-07
:
  • Drug: vorinostat
  • Genetic: protein expressi
Completed : Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
: Ductal Carcinoma in Situ
: 2011-06-09
: Drug: SOM 230 / Pasireotide SOM230/Pasireotide is a multi-receptor targeted somatostatin analogue. In th
Terminated : Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ
: Breast Cancer
: 2006-02-09
:
  • Drug: Tamoxifen Tamoxifen may